4//SEC Filing
Luo Ying 4
Accession 0001140361-23-054522
CIK 0001124105other
Filed
Nov 21, 7:00 PM ET
Accepted
Nov 22, 7:55 PM ET
Size
10.8 KB
Accession
0001140361-23-054522
Insider Transaction Report
Form 4
Luo Ying
Director
Transactions
- Other
Common Stock
2023-10-30+2,840,376→ 2,840,376 total(indirect: By Spouse) - Award
Stock Option (Right to Buy)
2023-11-20+2,262,755→ 2,262,755 total(indirect: By Spouse)Exercise: $0.75Exp: 2030-10-31→ Common Stock (2,262,755 underlying) - Award
Stock Option (Right to Buy)
2023-11-20+3,350,897→ 3,350,897 totalExercise: $0.75Exp: 2030-10-31→ Common Stock (3,350,897 underlying)
Footnotes (4)
- [F1]Represents the number of shares of common stock of the Issuer received by the spouse of the Reporting Person in exchange for the shares of Aaring Limited, a company incorporated under the laws of Hong Kong with limited liability, held by the spouse of the Reporting Person pursuant to that certain Business Combination Agreement, dated as of December 26, 2022 and as amended on March 29, 2023 and August 30, 2023 (the "Business Combination Agreement"), by and among Catalyst Biosciences, Inc., a Delaware corporation, GNI USA, Inc., a Delaware corporation, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability,
- [F2][cont'd from FN 1] GNI Hong Kong Limited, a company incorporated under the laws of Hong Kong with limited liability, Shanghai Genomics, Inc., a company organized under the laws of the People's Republic of China, the Minority Holders (as defined therein) and Continent Pharmaceuticals Inc., a Cayman Islands company limited by shares. Pursuant to the terms of the Business Combination Agreement, on October 30, 2023, the Issuer acquired an indirect controlling interest in Beijing Continent Pharmaceuticals Co., Ltd, a company organized under the laws of the People's Republic of China ("Beijing Continent").
- [F3]Beijing Continent terminated its 2021 Stock Incentive Plan (the "2021 Plan") and each option (a "BC Option") to purchase common shares of Beijing Continent outstanding under the 2021 Plan was terminated and replaced with options granted pursuant to a sub-plan for Chinese participants under the Issuer's 2023 Omnibus Incentive Plan that are substantially similar in all material respects to the BC Options previously outstanding under the 2021 Plan.
- [F4]These options are vested in full.
Documents
Issuer
GYRE THERAPEUTICS, INC.
CIK 0001124105
Entity typeother
Related Parties
1- filerCIK 0001959160
Filing Metadata
- Form type
- 4
- Filed
- Nov 21, 7:00 PM ET
- Accepted
- Nov 22, 7:55 PM ET
- Size
- 10.8 KB